Patient-derived organoids in disease modeling
In an exclusive interview with Commercial Organoid Innovation Director Nikki Carter, Drug Target Review explores the power of patient-derived organoids (PDOs) in drug discovery.
These “patient in a dish” models, as Nikki explains, are 3D cell structures cultivated from tissue samples that offer an opportunity to bridge the gap between these more human-relevant models and traditional 2D cell cultures or animal models. Here she explores translatability, technological advancements, and the integration of artificial intelligence (AI), envisioning the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalized clinical treatments, ultimately reducing costs and improving patient outcomes.